2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W795960
    D-myo-Inositol 1,4,5-trisphosphate sodium salt 108340-81-4 98%
    D-myo-inositol 1,4,5-trisphosphate sodium salt is a widely distributed intracellular second messenger. D-myo-inositol 1,4,5-trisphosphate sodium salt acts as a potent agonist of the Ins (1,4,5) P3 receptor with an EC50 of 0.12 μM and inhibits bovine PLC-δ1, with an IC50 of 5.4 μM for binding and an IC50 of 12.4 μM for hydrolysis. D-myo-inositol 1,4,5-trisphosphate sodium saltis metabolized into Ins (1,4) P2 and Ins (1,3,4,5) P4. D-myo-inositol 1,4,5-trisphosphate sodium salt mediates various cellular processes, including growth, development, fertilization, secretion, contraction and neuromodulation. D-myo-inositol 1,4,5-trisphosphate sodium salt inhibits PIP2 hydrolysis and Ca2+-ATPase activity. D-myo-inositol 1,4,5-trisphosphate sodium salt is used for cardiac preconditioning, exerts cardioprotective effects and mimics ischemic preconditioning. D-myo-inositol 1,4,5-trisphosphate sodium salt is applied in studies related to intracellular calcium and phosphoinositol signaling pathways.
    D-myo-Inositol 1,4,5-trisphosphate sodium salt
  • HY-W822786
    GR125487 144625-67-2
    GR125487 is a highly selective and potent 5-HT4 receptor (5-HT4 receptor) antagonist with a Kd value of 0.1 nM. GR125487 has an extremely low affinity for 5-HT3 receptors (Kd > 1 μM). GR125487 completely antagonizes the memory-promoting effect of BIMU1, and its administration alone has no significant effect on basic social memory. GR125487 can be used for the study of social olfactory memory.
    GR125487
  • HY-W835959
    ACI-3024 2361566-66-5
    ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases.
    ACI-3024
  • HY-W839206
    NOS-IN-4 3737-39-1
    NOS-IN-4 (Compound 3) is a neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 4.00 μM that inhibits nNOS activity. The combined use of alpha-lipoic acid and NOS-IN-4 has a protective effect against MPTP (HY-W114750)-induced dopamine depletion in the mouse brain. NOS-IN-4 can be used for the research of neurological disease.
    NOS-IN-4
  • HY-W841840
    SR94 550301-63-8 98%
    SR94, a SR17 derivative, is a SIRT2 inhibitor that contains an arbitrary 6-member ring and different R2 groups. SR94 is promising for research of cancer, ischemia-reperfusion and neurodegenerative diseases.
    SR94
  • HY-W842364
    CK1δ-IN-3 571174-12-4 98%
    CK1δ-IN-3 (compound 376) is a casein kinase 1δ (CK1δ) inhibitor. CK1δ-IN-3 can be utilized in neurodegenerative disorders research.
    CK1δ-IN-3
  • HY-W844558
    Protein kinase inhibitor 11 721964-51-8 98.28%
    Protein kinase inhibitor 11 (Compound I-96) is a protein kinase inhibitor that can inhibit the activity of PIM-1, CDK-2, GSK-3, and SRC. Protein kinase inhibitor 11 holds promise for research in cancer, immune disorders, and neurodegenerative diseases.
    Protein kinase inhibitor 11
  • HY-W856819
    Eseroline 469-22-7 98%
    Eseroline is a potent μ-opioid receptor agonist, which is the hydrolytic metabolite of Physostigmine (HY-N6608). Eseroline is a selective and competitive acetylcholinesterase (AChE) inhibitor, with its Ki values for AChE and BuChE being 0.1 μM and 200 μM respectively. Eseroline has nicotinic acetylcholine receptor allosteric enhancing ligand (nAChR-APL) activity, meaning it does not activate the receptor but significantly enhances the signal transduction of Ach triggered by the receptor. Eseroline is neurotoxic, causing cell membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Eseroline can be used for the study of Alzheimer's disease.
    Eseroline
  • HY-W882667
    Pregn-5-en-3β-ol 2862-58-0
    Pregn-5-en-3β-ol, a steroid compound, when formulated as the biscarboxylic acid hemiesters along with androst-5-en-3β-ol, serves as a potent positive allosteric modulator of NMDA (N-methyl-D-aspartate) receptors, making it applicable for research into psychiatric disorders.
    Pregn-5-en-3β-ol
  • HY-W903631
    SB-216641 170230-39-4
    SB-216641 is a selective 5-HT1b antagonist. SB-216641 mildly prevents stress-induced behavioral performance dysregulations.
    SB-216641
  • HY-W909149
    TAAR1 agonist 3 1804129-70-1 98%
    TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC50=7.6). TAAR1 agonist 3 is also a full agonist of the α2A receptor (pEC50=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases.
    TAAR1 agonist 3
  • HY-W909173
    TAAR1 agonist 2 1804128-38-8 98%
    TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC50=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC50=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases.
    TAAR1 agonist 2
  • HY-W966480
    Oxindanac 68548-99-2
    Oxindanac is a nonsteroidal anti-inflammatory agent. Oxindanac produces inhibition of serum TxB2 production. Oxindanac reduces the volume of swelling. Oxindanac shows analgesic activity.
    Oxindanac
  • HY-W975902
    MDL-27531 116850-44-3 98%
    MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction.
    MDL-27531
  • HY-W987949
    Z-4105 119737-52-9 98%
    Z-4105 is an orally active nootropic agent. Z-4105 reverses the amnesic effects of electroconvulsive shock (ECS) and methylazoxymethanol acetate (MAM), and improves learning and memory functions. Z-4105 enhances the activity of the brain cholinergic system without affecting other neurotransmitter systems. Z-4105 significantly alleviates neuropathic pain in rats. Z-4105 can be used in the research of neuropathic pain and brain dysfunction.
    Z-4105
  • HY-Y0123S1
    DL-Tyrosine-d7 402835-78-3 98%
    DL-Tyrosine-d7 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-d7
  • HY-Y0123S2
    DL-Tyrosine-d2 35693-18-6 98%
    DL-Tyrosine-d2 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-d2
  • HY-Y0123S3
    DL-Tyrosine-d3 73036-42-7 98%
    DL-Tyrosine-d3 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-d3
  • HY-Y0123S4
    DL-Tyrosine-d4 74004-34-5
    DL-Tyrosine-d4 is the deuterium labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-d4
  • HY-Y0123S5
    DL-Tyrosine-13C 93627-94-2
    DL-Tyrosine-13C is the 13C-labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
    DL-Tyrosine-13C
Cat. No. Product Name / Synonyms Application Reactivity